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Abstract
We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine
administration in a 29-year Nigerian female patient with generalized tonic-clonic seizures. Although
asymptomatic, the biochemical abnormality improved after discontinuation of carbamazepine.
Hyponatraemia developed after rechallenge with controlled release carbamazepine. The authors suggest
that serum sodium levels be carried out before commencement of carbamazepine and caution be used in
prescribing carbamazepine to patients with low or borderline low sodium values.
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Résumé
Nous rapportons le syndrome de l’antidicirose inappropriée comme beaucoup plus tôt aux effets
secondaires de l’administration carbamazepine chez une malade nigériane âgée de 29 ans avec de la
convulsion toniques clonique généralisée. Bien que asymptomatique, l’anomalie biochimique avait
amélioré après l’arrêt de la carbamazepine. L’hyponatemie avait développé après ré administration de la
carbamazepine contrôlée. Les auteurs suggèrent que les niveaux de sérum de sodium devront être
effectués avant le début de la carbamazephine et de prudence être utilisée dans l’ordonnance de la
carbamazepine pour des patients atteints de la faible ou basse limite des valeurs de sodium.
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Introduction
Carbamazepine is widely used in Nigeria in the
treatment of seizure disorders and of trigeminal and
other neuralgias. It has found a role in the prophylaxis
of affective disorders.1 It is used in adults and children
in the prophylaxis management of partial seizures,
generalized tonic-clonic seizures and mixed seizure
patterns. It has been used in the symptomatic
management of the acute phase of schizophrenia as an
adjunct to therapy with an antipsychotic agent in
patients who fail to respond to an adequate trial of the
antipsychotic alone.2 Although hyponatraemia is a
well-recognized side-effect of carbamazepine therapy,
it has previously been reported only at moderate or
high doses and usually after weeks or months of
treatment.3-9 This paper reports a case of
carbamazepine-induced hyponatraemia in a young
Nigerian woman being treated for generalized tonic-
clonic seizures.
Case report
A 29-year-old Nigerian female presents with a
3-month history of generalized tonic-clonic seizures.
Her first seizure occurred when she was 17 years, and
her second seizure occurred 2 years after that. She
chose not to start antiepileptic drugs at that time
because the seizures were rare, but she has now had
five seizures over the past 6 months. After seven days
of treatment with carbamazepine 200mg twice daily
increasing to 400mg twice daily, a routine estimation
of plasma electrolytes gave sodium of 121 mmol/l
with chloride of 89 mmol/l; other results were within
normal limits. She had a normal plasma sodium level
of 135mmol/l before commencement of
carbamazepine therapy. She did not use other
medications such as diuretics and antipsychotics that
could cause hyponatraemia. Carbamazepine was
discontinued, leading to a rise in plasma sodium to
reach a normal value after two weeks without any
medication. Physical examination and investigations,
including chest and skull radiographs, showed no
alternative explanation for the hyponatraemia such as
meningitis, encephalitis or pulmonary tuberculosis.
The suspected role of carbamazepine in
producing this effect was confirmed by a period of
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rechallenge with the drug, during which plasma
electrolyte levels were monitored daily. Although
plasma carbamazepine levels could not be monitored,
the dose given was 200mg on the first day and 200mg
twice daily thereafter. On day 3, after a total dose of
600mg, the sodium level was 132 mmol/L, just below
the laboratory’s normal range 135-145 mmol/L. The
following day it was 128 mmol/L with a plasma
osmolality of 255 mmol/L and urine osmolality of 325
mmol/L. On stopping carbamazepine, the electrolyte
returned to normal in four days. At no time during the
period of hyponatraemia did the patient show
symptoms. Her medication was changed to phenytoin
capsule 300mg nocte.
Discussion
The goal of treatment with antiepileptic drugs (AEDs)
is complete control of seizures without side effects.
The choice of initial therapy is perhaps the most
critical juncture in the care of epilepsy patients, as
many patients will remain on this therapy for years, if
not a lifetime. There is no such thing as an ‘ideal’
AED that would be the first choice in patients with
epilepsy or even all patients with a given epilepsy
syndrome. This case demonstrates the potentially
profound disturbance of water balance, which can
occur as result of carbamazepine monotherapy. We
attributed the acute hyponatraemia to carbamazepine
since there was no concomitant use of medications
associated with hyponatraemia. Carbamazepine has
led to hyponatraemia in patients with epilepsy,
neuralgia, mental retardation, and psychiatric
disorders with a frequency varying from 4.8 to 40%.10
It shows that this side-effect can occur at lower doses
and after much shorter periods than has previously
been recognized.
Possible mechanisms for the antidiuretic
effects of carbamazepine have been proposed. Altered
sensitivity to serum osmolality by the hypothalamic
osmoreceptors appear likely, but an increased
sensitivity of the renal tubules to circulating
antidiuretic hormone cannot be explained. It suggests
the need to estimate plasma electrolytes in patients
complaining of side-effect such as nausea, headache
and dizziness-all symptoms of hyponatraemia-in the
first few days of carbamazepine therapy. Several risk
factors have been reported to increase the risk of
hyponatraemia including age greater than 40 years,
concomitant use of medications associated with
hyponatraemia, menstruation, psychiatric conditions,
surgery, psychogenic polydipsia and female gender.11
Most patients with carbamazepine-induced
hyponatraemia are asymptomatic. In rare cases, water
intoxication has been reported,10 necessitating
treatment discontinuation. We therefore suggest that
caution be used in prescribing carbamazepine to
patients with low or borderline sodium values.
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